https://orcid.org/0000-0003-1420-4015
Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Syamala R. Thimmiraju, Jason T. Kimata & Jeroen Pollet. (2024) Pseudoviruses, a safer toolbox for vaccine development against enveloped viruses. Expert Review of Vaccines 23:1, pages 174-185.
Read now
Read now
Peter J. Hotez, Rakesh Adhikari, Wen-Hsiang Chen, Yi-Lin Chen, Portia Gillespie, Nelufa Y. Islam, Brian Keegan, Rakhi Tyagi Kundu, Jungsoon Lee, Zhuyun Liu, Jason T. Kimata, Numan Oezguen, Jeroen Pollet, Cristina Poveda, Kay Razavi, Shannon E. Ronca, Ulrich Strych, Syamala R. Thimmiraju, Leroy Versteeg, Maria Jose Villar-Mondragon, Junfei Wei, Bin Zhan & Maria Elena Bottazzi. (2023) From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Review of Vaccines 22:1, pages 495-500.
Read now
Read now
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Srikanth Adabala, Aditya Sri Javvadi, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Akshay Binayke, Aymaan Zaheer, Amit Awasthi, Chandramani Singh, Venkateshwar Rao A, Indranil Basu, Khobragade Akash Ashok Kumar & Anil Kumar Pandey. (2023) Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Feixia Gao, Mei Zheng, Jiangfeng Fan, Yahong Ding, Xueying Liu, Min Zhang, Xin Zhang, Jinrong Dong, Xu Zhou, Jian Luo & Xiuling Li. (2023) A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Ting Zhang, Ningchen Zheng, Zhirong Wang & Xuemei Xu. (2023) Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Sakshi Bajoria, Kawaljit Kaur, Ozan S. Kumru, Greta Van Slyke, Jennifer Doering, Hayley Novak, Sergio A. Rodriguez Aponte, Neil C. Dalvie, Christopher A. Naranjo, Ryan S. Johnston, Judith Maxwell Silverman, Harry Kleanthous, J. Christopher Love, Nicholas J. Mantis, Sangeeta B. Joshi & David B. Volkin. (2022) Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Articles from other publishers (37)
Altijana Hromić-Jahjefendić, Kenneth Lundstrom, Muhamed Adilović, Alaa A.A. Aljabali, Murtaza M. Tambuwala, Ángel Serrano-Aroca & Vladimir N. Uversky. (2024) Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines. Autoimmunity Reviews 23:3, pages 103508.
Crossref
Crossref
Alejandra Wong-Arce, Omar Gonzalez-Ortega, Andrea Romero-Maldonado, Arleth Miranda-López, Mariano García-Soto, Susan Farfán-Castro, Lourdes Betancourt-Mendiola, Samaporn Teeravechyan, Kanjana Srisutthisamphan, Mauricio Comas-García, Karla I. Solís Andrade & Sergio Rosales-Mendoza. (2024) Production and Immunogenicity Assessment of LTp50: An Escherichia coli-Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein. Pharmaceuticals 17:3, pages 302.
Crossref
Crossref
Neetu Rajak, Trishna Dey, Yash Sharma, Vedanth Bellad & Pundi N. Rangarajan. (2024) Unlocking Nature’s Toolbox: glutamate-inducible recombinant protein production from the Komagatella phaffii PEPCK promoter. Microbial Cell Factories 23:1.
Crossref
Crossref
Kenneth Lundstrom. (2024) COVID-19 Vaccines: Where Did We Stand at the End of 2023?. Viruses 16:2, pages 203.
Crossref
Crossref
He-Chin Hsieh, Chung-Chu Chen, Pin-Han Chou, Wen-Chun Liu & Suh-Chin Wu. (2023) Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit. Antiviral Research 220, pages 105752.
Crossref
Crossref
Aishi Dasgupta, Shon Gangai, Rishikesh Narayan & Shobhna Kapoor. (2023) Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions. Journal of Medicinal Chemistry 66:21, pages 14411-14433.
Crossref
Crossref
Richard Mahoney, Peter J. Hotez & Maria Elena Bottazzi. (2023) Global regulatory reforms to promote equitable vaccine access in the next pandemic. PLOS Global Public Health 3:10, pages e0002482.
Crossref
Crossref
Gaurav Nagar, Siddharth Jain, Meghraj Rajurkar, Rakesh Lothe, Harish Rao, Sourav Majumdar, Manish Gautam, Sergio A. Rodriguez-Aponte, Laura E. Crowell, J. Christopher Love, Prajakta Dandekar, Amita Puranik, Sunil Gairola, Umesh Shaligram & Ratnesh Jain. (2023) Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast. Vaccines 11:10, pages 1602.
Crossref
Crossref
Syamala Rani Thimmiraju, Rakesh Adhikari, Maria Jose Villar, Jungsoon Lee, Zhuyun Liu, Rakhi Kundu, Yi-Lin Chen, Suman Sharma, Karm Ghei, Brian Keegan, Leroy Versteeg, Portia M. Gillespie, Allan Ciciriello, Nelufa Y. Islam, Cristina Poveda, Nestor Uzcategui, Wen-Hsiang Chen, Jason T. Kimata, Bin Zhan, Ulrich Strych, Maria Elena Bottazzi, Peter J. Hotez & Jeroen Pollet. (2023) A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines 11:10, pages 1557.
Crossref
Crossref
Sedthawut Laotee, Methawee Duangkaew, Araya Jivapetthai, Kittipan Tharakhet, Papatsara Kaewpang, Eakachai Prompetchara, Supaporn Phumiamorn, Sompong Sapsutthipas, Sakalin Trisiriwanich, Thitiporn Somsaard, Sittiruk Roytrakul, Parichat Duangkhae, Boonsri Ongpipattanakul, Patanachai Limpikirati, Natapol Pornputtapong & Wanatchaporn Arunmanee. (2023) CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2. PLOS ONE 18:7, pages e0288486.
Crossref
Crossref
Elliot Campbell, Julie Dobkin, Louis J. Osorio, Afsal Kolloli, Santhamani Ramasamy, Ranjeet Kumar, Derek B. Sant’Angelo, Selvakumar Subbian, Lisa K. Denzin & Stephen Anderson. (2023) A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. Vaccines 11:4, pages 832.
Crossref
Crossref
Sibel Kalyoncu, Semiramis Yilmaz, Ayca Zeybek Kuyucu, Dogu Sayili, Olcay Mert, Hakan Soyturk, Seyda Gullu, Huseyin Akinturk, Erhan Citak, Merve Arslan, Melda Guray Taskinarda, Ibrahim Oguzhan Tarman, Gizem Yilmazer Altun, Ceren Ozer, Ridvan Orkut, Aysegul Demirtas, Idil Tilmensagir, Umur Keles, Ceren Ulker, Gizem Aralan, Yavuz Mercan, Muge Ozkan, Hasan Onur Caglar, Gizem Arik, Mehmet Can Ucar, Muzaffer Yildirim, Tugce Canavar Yildirim, Dilara Karadag, Erhan Bal, Aybike Erdogan, Serif Senturk, Serdar Uzar, Hakan Enul, Cumhur Adiay, Fahriye Sarac, Arzu Tas Ekiz, Irem Abaci, Ozge Aksoy, Hivda Ulbegi Polat, Saban Tekin, Stefan Dimitrov, Aykut Ozkul, Gerhard Wingender, Ihsan Gursel, Mehmet Ozturk & Mehmet Inan. (2023) Process development for an effective COVID-19 vaccine candidate harboring recombinant SARS-CoV-2 delta plus receptor binding domain produced by Pichia pastoris. Scientific Reports 13:1.
Crossref
Crossref
Gerrit Koopman, Mario Amacker, Toon Stegmann, Ernst J. Verschoor, Babs E. Verstrepen, Farien Bhoelan, Denzel Bemelman, Kinga P. Böszörményi, Zahra Fagrouch, Gwendoline Kiemenyi-Kayere, Daniella Mortier, Dagmar E. Verel, Henk Niphuis, Roja Fidel Acar, Ivanela Kondova, Yolanda S. Kap, Willy M. J. M. Bogers, Petra Mooij & Sylvain Fleury. (2023) A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. Scientific Reports 13:1.
Crossref
Crossref
Thayne H. Dickey, Rui Ma, Sachy Orr-Gonzalez, Tarik Ouahes, Palak Patel, Holly McAleese, Brandi Butler, Elizabeth Eudy, Brett Eaton, Michael Murphy, Jennifer L. Kwan, Nichole D. Salinas, Michael R. Holbrook, Lynn E. Lambert & Niraj H. Tolia. (2023) Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines. Cell Reports 42:3, pages 112266.
Crossref
Crossref
Ehsan Raoufi, Fatemeh Hosseini, Bahman Onagh, Mohammad Salehi-Shadkami, Marjan Mehrali, Monireh Mohsenzadegan, Jim Q. Ho, Banafsheh Bigdelou, Mohammad Reza Sepand, Thomas J. Webster, Steven Zanganeh & Mohammad M. Farajollahi. (2023) Designing and developing a sensitive and specific SARS-CoV-2 RBD IgG detection kit for identifying positive human samples. Clinica Chimica Acta 542, pages 117279.
Crossref
Crossref
Etsuro Nanishi, Francesco Borriello, Hyuk-Soo Seo, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Jing Chen, Joann Diray-Arce, Kijun Song, Andrew Z. Xu, Soumik Barman, Manisha Menon, Danica Dong, Timothy M. Caradonna, Jared Feldman, Blake M. Hauser, Aaron G. Schmidt, Lindsey R. Baden, Robert K. Ernst, Carly Dillen, Jingyou Yu, Aiquan Chang, Luuk Hilgers, Peter Paul Platenburg, Sirano Dhe-Paganon, Dan H. Barouch, Al Ozonoff, Ivan Zanoni, Matthew B. Frieman, David J. Dowling & Ofer Levy. (2023) Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. npj Vaccines 8:1.
Crossref
Crossref
Angelina Kovalenko, Ekaterina Ryabchevskaya, Ekaterina Evtushenko, Nikolai Nikitin & Olga Karpova. (2023) Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress. International Journal of Molecular Sciences 24:2, pages 1701.
Crossref
Crossref
Kumar Pushkar, Saurabh Bobdey, Rituraj Kotoki, Kunal Koundinya, PriyankaSharma Michael & SK Kaushik. (2023) Corbevax vaccine side effects in children of age group 12–14 years: A prospective observational study. Journal of Marine Medical Society 0:0, pages 0.
Crossref
Crossref
Ram Nechooshtan, Sharon Ehrlich, Marika Vitikainen, Arik Makovitzki, Eyal Dor, Hadar Marcus, Idan Hefetz, Shani Pitel, Marilyn Wiebe, Anne Huuskonen, Lilach Cherry, Edith Lupu, Yehuda Sapir, Tzvi Holtzman, Moshe Aftalion, David Gur, Hadas Tamir, Yfat Yahalom-Ronen, Yuval Ramot, Noam Kronfeld, David Zarling, Anne Vallerga, Ronen Tchelet, Abraham Nyska, Markku Saloheimo, Mark Emalfarb & Yakir Ophir. (2022) Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge. Vaccines 10:12, pages 2119.
Crossref
Crossref
Agustín Valenzuela-Fernández, Romina Cabrera-Rodriguez, Laura Ciuffreda, Silvia Perez-Yanes, Judith Estevez-Herrera, Rafaela González-Montelongo, Julia Alcoba-Florez, Rodrigo Trujillo-González, Diego García-Martínez de Artola, Helena Gil-Campesino, Oscar Díez-Gil, José M. Lorenzo-Salazar, Carlos Flores & Jonay Garcia-Luis. (2022) Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Erin M. Euliano, Alexandros A. Sklavounos, Aaron R. Wheeler & Kevin J. McHugh. (2022) Translating diagnostics and drug delivery technologies to low-resource settings. Science Translational Medicine 14:666.
Crossref
Crossref
Marianna Teixeira de Pinho Favaro, Jan Atienza-Garriga, Carlos Martínez-Torró, Eloi Parladé, Esther Vázquez, José Luis Corchero, Neus Ferrer-Miralles & Antonio Villaverde. (2022) Recombinant vaccines in 2022: a perspective from the cell factory. Microbial Cell Factories 21:1.
Crossref
Crossref
Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Chandramani Singh & Venkateshwar Rao A. (2022) Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials. eBioMedicine 83, pages 104217.
Crossref
Crossref
Hongguan Xing, Liyan Zhu, Pingping Wang, Guoping Zhao, Zhihua Zhou, Yi Yang, Hong Zou & Xing Yan. (2022) Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface. Frontiers in Immunology 13.
Crossref
Crossref
Guinevere G. Connelly, Orville O. Kirkland, Seven Bohannon, Daniel C. Lim, Robert M. Wilson, Edward J. Richards, Dousabel M. Tay, Hyuk Jee, Riley D. Hellinger, Ngoc K. Hoang, Liang Hao, Arnav Chhabra, Carmen Martin-Alonso, Edward K.W. Tan, Angela N. Koehler, Michael B. Yaffe, Wendy B. London, Pui Y. Lee, Florian Krammer, Robert C. Bohannon, Sangeeta N. Bhatia, Hadley D. Sikes & Hojun Li. (2022) Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Reports Methods 2:8, pages 100273.
Crossref
Crossref
Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, Eliana F. Castro, Laura A. Bruno, William B. Stone, Paula S. Pérez, Maria Laura Darriba, Lucia B. Chemes, Julieta Alcain, Ignacio Mazzitelli, Augusto Varese, Melina Salvatori, Albert J. Auguste, Diego E. Álvarez, Karina A. Pasquevich & Juliana Cassataro. (2022) A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Frontiers in Immunology 13.
Crossref
Crossref
Darielys Santana-Mederos, Rocmira Perez-Nicado, Yanet Climent, Laura Rodriguez, Belinda Sanchez Ramirez, Sonia Perez-Rodriguez, Meybi Rodriguez, Claudia Labrada, Tays Hernandez, Marianniz Diaz, Ivette Orosa, Ubel Ramirez, Reynaldo Oliva, Raine Garrido, Felix Cardoso, Mario Landys, Roselyn Martinez, Humberto Gonzalez, Tamara Hernandez, Rolando Ochoa-Azze, Jose L. Perez, Juliet Enriquez, Nibaldo Gonzalez, Yenicet Infante, Luis A. Espinosa, Yassel Ramos, Luis Javier González, Carmen Valenzuela, Ana Victoria Casadesus, Briandy Fernandez, Gertrudis Rojas, Beatriz Pérez-Massón, Yaima Tundidor, Ernesto Bermudez, Claudia A. Plasencia, Tammy Boggiano, Eduardo Ojito, Fabrizio Chiodo, Sonsire Fernandez, Françoise Paquet, Cheng Fang, Guang-Wu Chen, Daniel G. Rivera, Yury Valdes-Balbin, Dagmar Garcia-Rivera & Vicente Verez Bencomo. (2022)
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and
Neisseria meningitidis
outer membrane vesicles
. RSC Chemical Biology 3:2, pages 242-249.
Crossref
Crossref
Kwang Poo Chang, Joseph M. Reynolds, Ying Liu & Johnny J. He. (2022) Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?. Vaccines 10:2, pages 248.
Crossref
Crossref
Neil C. Dalvie, Andrew M. Biedermann, Sergio A. Rodriguez‐Aponte, Christopher A. Naranjo, Harish D. Rao, Meghraj P. Rajurkar, Rakesh R. Lothe, Umesh S. Shaligram, Ryan S. Johnston, Laura E. Crowell, Seraphin Castelino, Mary K. Tracey, Charles A. Whittaker & J. Christopher Love. (2021)
Scalable, methanol‐free manufacturing of the SARS‐CoV‐2 receptor‐binding domain in engineered
Komagataella phaffii
. Biotechnology and Bioengineering 119:2, pages 657-662.
Crossref
Crossref
Peter J. Hotez & Maria Elena Bottazzi. (2022) Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annual Review of Medicine 73:1, pages 55-64.
Crossref
Crossref
Etsuro Nanishi, Francesco BorrielloTimothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Robert E. Haupt, Hyuk-Soo Seo, Simon D. van Haren, Cecilia B. Cavazzoni, Byron Brook, Soumik Barman, Jing ChenJoann Diray-Arce, Simon Doss-Gollin, Maria De Leon, Alejandra Prevost-Reilly, Katherine Chew, Manisha MenonKijun Song, Andrew Z. Xu, Timothy M. Caradonna, Jared Feldman, Blake M. Hauser, Aaron G. Schmidt, Amy C. Sherman, Lindsey R. BadenRobert K. Ernst, Carly Dillen, Stuart M. Weston, Robert M. Johnson, Holly L. HammondRomana MayerAllen Burke, Maria E. Bottazzi, Peter J. HotezUlrich Strych, Aiquan Chang, Jingyou Yu, Peter T. Sage, Dan H. Barouch, Sirano Dhe-Paganon, Ivan Zanoni, Al Ozonoff, Matthew B. Frieman, Ofer Levy & David J. Dowling. (2022) An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine 14:629.
Crossref
Crossref
Luis Ariel Espinosa, Yassel Ramos, Ivan Andújar, Enso Onill Torres, Gleysin Cabrera, Alejandro Martín, Diamilé Roche, Glay Chinea, Mónica Becquet, Isabel González, Camila Canaán-Haden, Elías Nelson, Gertrudis Rojas, Beatriz Pérez-Massón, Dayana Pérez-Martínez, Tamy Boggiano, Julio Palacio, Sum Lai Lozada Chang, Lourdes Hernández, Kathya Rashida de la Luz Hernández, Saloheimo Markku, Marika Vitikainen, Yury Valdés-Balbín, Darielys Santana-Medero, Daniel G. Rivera, Vicente Vérez-Bencomo, Mark Emalfarb, Ronen Tchelet, Gerardo Guillén, Miladys Limonta, Eulogio Pimentel, Marta Ayala, Vladimir Besada & Luis Javier González. (2021) In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI–MS spectrum. Analytical and Bioanalytical Chemistry 413:30, pages 7559-7585.
Crossref
Crossref
Harry Kleanthous, Judith Maxwell Silverman, Karen W. Makar, In-Kyu Yoon, Nicholas Jackson & David W. Vaughn. (2021) Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines 6:1.
Crossref
Crossref
Neil C. Dalvie, Sergio A. Rodriguez-AponteBrittany L. HartwellLisa H. Tostanoski, Andrew M. BiedermannLaura E. CrowellKawaljit KaurOzan S. KumruLauren CarterJingyou YuAiquan Chang, Katherine McMahanThomas CourantCelia LebasAshley A. Lemnios, Kristen A. Rodrigues, Murillo SilvaRyan S. JohnstonChristopher A. NaranjoMary Kate TraceyJoseph R. Brady, Charles A. Whittaker, Dongsoo YunNatalie BrunetteJing Yang Wang, Carl WalkeyBrooke Fiala, Swagata KarMaciel PortoMegan LokHanne AndersenMark G. Lewis, Kerry R. LoveDanielle L. CampJudith Maxwell SilvermanHarry KleanthousSangeeta B. JoshiDavid B. VolkinPatrice M. Dubois, Nicolas CollinNeil P. KingDan H. BarouchDarrell J. Irvine & J. Christopher Love. (2021) Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. Proceedings of the National Academy of Sciences 118:38.
Crossref
Crossref
Daniel Ellis, Natalie Brunette, Katharine H. D. Crawford, Alexandra C. Walls, Minh N. Pham, Chengbo Chen, Karla-Luise Herpoldt, Brooke Fiala, Michael Murphy, Deleah Pettie, John C. Kraft, Keara D. Malone, Mary Jane Navarro, Cassandra Ogohara, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Maggie Ahlrichs, Max Johnson, Alyssa Blackstone, Lauren Carter, Tyler N. Starr, Allison J. Greaney, Kelly K. Lee, David Veesler, Jesse D. Bloom & Neil P. King. (2021) Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Frontiers in Immunology 12.
Crossref
Crossref
Subhash Thuluva, Vikram Paradkar, Kishore Thuraga, Subbareddy Gunneri, Vijay Yerroju, Rammohanreddy Mogulla, Mahesh Kyasani, Senthilkumar Manoharan, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, CM Singh & Venkateshwar Rao A. (2022) Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. SSRN Electronic Journal.
Crossref
Crossref
Subhash Thuluva, Vikram Paradkar, Kishore Thuraga, Subbareddy Gunneri, Vijay Yerroju, Rammohanreddy Mogulla, Mahesh Kyasani, Senthilkumar Manoharan, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Chandramani Singh & Venkateshwar Rao A. (2022) Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies. SSRN Electronic Journal.
Crossref
Crossref